Cargando…
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramuciruma...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/ https://www.ncbi.nlm.nih.gov/pubmed/36451771 http://dx.doi.org/10.1155/2022/2476469 |
_version_ | 1784840198059720704 |
---|---|
author | Tang, Lingxue Wang, Tong Zhang, Qianqian Yu, Sheng Li, Wen Yao, Senbang Cheng, Huaidong |
author_facet | Tang, Lingxue Wang, Tong Zhang, Qianqian Yu, Sheng Li, Wen Yao, Senbang Cheng, Huaidong |
author_sort | Tang, Lingxue |
collection | PubMed |
description | Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramucirumab, which included 11 global, double-blind, phase 3 randomized controlled trials with a total of 7410 patients. Subgroup analysis based on different cancer types showed that standard regimens plus ramucirumab significantly increased progression-free survival and overall survival compared with placebo groups in patients with advanced non-small-cell lung cancer (NSCLC), hepatocellular carcinoma, gastric cancer, or GEJ adenocarcinoma. Although a higher proportion of patients achieved overall response and disease control than those treated with placebo, the overall response was not statistically significant between the two groups in advanced NSCLC. Grade 3 or worse treatment-emergent adverse events (TEAEs) that occurred in at least 5% of patients were neutropenia (30.5% in the ramucirumab group vs. 23.5% in the placebo group), leucopenia (14.8% vs. 9.2%), weight decreased (14.2% vs. 8.0%), myalgia (11.7% vs. 7.7%), fatigue (10.9% vs. 7.7%), hypertension (9.2% vs. 2.3%), and anaemia (6.2% vs. 7.7%). In the TEAEs of special interest, the ramucirumab group had a significantly higher incidence of bleeding (mainly grade 1-2 epistaxis and gastrointestinal bleeding), hypertension, proteinuria, liver injury/failure (grade 1-2), venous thromboembolism (grade 1-2), and gastrointestinal perforation (grade ≧3) than the control group. |
format | Online Article Text |
id | pubmed-9705087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-97050872022-11-29 Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials Tang, Lingxue Wang, Tong Zhang, Qianqian Yu, Sheng Li, Wen Yao, Senbang Cheng, Huaidong J Oncol Review Article Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramucirumab, which included 11 global, double-blind, phase 3 randomized controlled trials with a total of 7410 patients. Subgroup analysis based on different cancer types showed that standard regimens plus ramucirumab significantly increased progression-free survival and overall survival compared with placebo groups in patients with advanced non-small-cell lung cancer (NSCLC), hepatocellular carcinoma, gastric cancer, or GEJ adenocarcinoma. Although a higher proportion of patients achieved overall response and disease control than those treated with placebo, the overall response was not statistically significant between the two groups in advanced NSCLC. Grade 3 or worse treatment-emergent adverse events (TEAEs) that occurred in at least 5% of patients were neutropenia (30.5% in the ramucirumab group vs. 23.5% in the placebo group), leucopenia (14.8% vs. 9.2%), weight decreased (14.2% vs. 8.0%), myalgia (11.7% vs. 7.7%), fatigue (10.9% vs. 7.7%), hypertension (9.2% vs. 2.3%), and anaemia (6.2% vs. 7.7%). In the TEAEs of special interest, the ramucirumab group had a significantly higher incidence of bleeding (mainly grade 1-2 epistaxis and gastrointestinal bleeding), hypertension, proteinuria, liver injury/failure (grade 1-2), venous thromboembolism (grade 1-2), and gastrointestinal perforation (grade ≧3) than the control group. Hindawi 2022-11-21 /pmc/articles/PMC9705087/ /pubmed/36451771 http://dx.doi.org/10.1155/2022/2476469 Text en Copyright © 2022 Lingxue Tang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Tang, Lingxue Wang, Tong Zhang, Qianqian Yu, Sheng Li, Wen Yao, Senbang Cheng, Huaidong Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title | Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title_full | Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title_fullStr | Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title_full_unstemmed | Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title_short | Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials |
title_sort | safety and efficacy of treatment with/without ramucirumab in advanced or metastatic cancer: a meta-analysis of 11 global, double-blind, phase 3 randomized controlled trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/ https://www.ncbi.nlm.nih.gov/pubmed/36451771 http://dx.doi.org/10.1155/2022/2476469 |
work_keys_str_mv | AT tanglingxue safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT wangtong safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT zhangqianqian safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT yusheng safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT liwen safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT yaosenbang safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials AT chenghuaidong safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials |